Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

Cash Flow Statement 

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Eli Lilly & Co., consolidated cash flow statement

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net income 5,240,400 6,244,800 5,581,700 6,193,700 8,318,400
Gain related to disposition of Elanco (3,680,500)
Gain on sale of antibiotic business in China (309,800)
Depreciation and amortization 1,527,300 1,522,500 1,547,600 1,323,900 1,232,600
Debt extinguishment loss 405,200 252,500
Change in deferred income taxes (2,341,000) (2,185,200) (802,300) (134,500) 62,400
Stock-based compensation expense 628,500 371,100 342,800 308,100 312,400
Net investment (gains) losses 23,500 420,000 (178,000) (1,438,500) (403,100)
Gains on sale of product rights (1,878,900) (156,500) (216,000)
Acquired in-process research and development 3,799,800 420,900 874,900 660,400 239,600
Other operating activities, net 295,500 461,300 727,400 333,900 499,300
Receivables, (increase) decrease (2,451,000) (299,600) (1,278,300) (1,350,200) (127,200)
Inventories, (increase) decrease (1,425,000) (599,700) (235,900) (533,400) (258,700)
Other assets, (increase) decrease (3,453,400) (793,500) 1,515,400 (457,100) (602,300)
Accounts payable and other liabilities, increase (decrease) 4,274,400 1,678,300 (1,023,800) 1,593,300 (699,000)
Other changes in operating assets and liabilities, net of acquisitions and divestitures (3,055,000) (14,500) (1,022,600) (747,400) (1,687,200)
Adjustments to reconcile net income to cash flows from operating activities (1,000,300) 839,600 1,679,000 305,900 (3,481,800)
Net cash provided by operating activities 4,240,100 7,084,400 7,260,700 6,499,600 4,836,600
Purchases of property and equipment (3,447,600) (1,854,300) (1,309,800) (1,387,900) (1,033,900)
Proceeds from sales and maturities of short-term investments 192,200 121,400 47,400 129,700 136,600
Purchases of short-term investments (98,200) (107,400) (83,500) (11,400) (42,700)
Proceeds from sales of and distributions from noncurrent investments 508,100 342,200 800,000 757,100 609,800
Purchases of noncurrent investments (730,800) (600,200) (929,900) (358,700) (247,500)
Proceeds from sale of product rights 1,604,300 95,800 216,000
Purchases of in-process research and development (3,944,500) (629,700) (563,400) (641,200) (319,600)
Cash paid for acquisitions, net of cash acquired (1,044,300) (327,200) (747,400) (849,300) (6,917,700)
Cash distributed to Elanco upon disposition (374,000)
Cash received for sale of antibiotic business in China 354,800
Other investing activities, net (191,900) (302,200) (191,700) 102,800 (248,700)
Net cash used for investing activities (7,152,700) (3,261,600) (2,762,300) (2,258,900) (8,082,900)
Dividends paid (4,069,300) (3,535,800) (3,086,800) (2,687,100) (2,409,800)
Net change in short-term borrowings 4,691,400 1,498,000 (4,000) (1,494,200) 995,400
Proceeds from issuance of long-term debt 3,958,500 2,410,800 2,062,300 6,556,400
Repayments of long-term debt (1,560,000) (1,905,400) (276,500) (2,866,400)
Purchases of common stock (750,000) (1,500,000) (1,250,000) (500,000) (4,400,000)
Other financing activities, net (335,000) (308,900) (295,900) (241,600) (200,100)
Net cash provided by (used for) financing activities 3,495,600 (5,406,700) (4,131,300) (3,137,100) (2,324,500)
Effect of exchange rate changes on cash and cash equivalents 168,600 (167,600) (205,700) 216,000 (89,900)
Net increase (decrease) in cash and cash equivalents 751,600 (1,751,500) 161,400 1,319,600 (5,660,700)
Cash and cash equivalents at beginning of year 2,067,000 3,818,500 3,657,100 2,337,500 7,998,200
Cash and cash equivalents at end of year 2,818,600 2,067,000 3,818,500 3,657,100 2,337,500

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Eli Lilly & Co. net cash provided by operating activities decreased from 2021 to 2022 and from 2022 to 2023.
Net cash used for investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Eli Lilly & Co. net cash used for investing activities decreased from 2021 to 2022 and from 2022 to 2023.
Net cash provided by (used for) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Eli Lilly & Co. net cash provided by (used for) financing activities decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.